Oxycodone
FDA-approved product (capsule, extended release, oral), marketed as Xtampza Er, Oxaydo, Oxycodone Hydrochloride and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic pain
- Drug dependence
- Pain
- Substance abuse
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural opium alkaloids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Oxycodone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- RegadenosonExisting use: Cardiovascular disease, Myocardial Perfusion Imaging48.4% AI-predicted activityagainst E. coli50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma48.2% AI-predicted activityagainst E. coliNo documented evidence found
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- ClozapineExisting use: Psychosis, Schizoaffective disorder, Schizophrenia48.1% AI-predicted activityagainst E. coli50+ registered studies
- FutibatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm48.0% AI-predicted activityagainst E. coli25 registered studies
- Atazanavir SulfateExisting use: HIV infection, HIV-1 infection, Infection and 1 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Daclatasvir DihydrochlorideExisting use: Chronic hepatitis C virus infection, Viral disease48.0% AI-predicted activityagainst E. coli2 registered studies
- AripiprazoleExisting use: Aggressive behavior, Agitation, Autism and 8 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Alclometasone DipropionateExisting use: Eye inflammation, Skin disease47.9% AI-predicted activityagainst E. coli2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery
NCT00679614 · start 2007-12-17
Registered record
- Registry ID
- NCT00679614
- Conditions
- Hip Arthroplasty; Knee Arthroplasty; Spinal Anesthesia
- Interventions
- tramacet, naloxone; tramacet; Acetaminophen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-12-17
- Completion
- 2011-05-31
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHip Arthroplasty; Knee Arthroplasty; Spinal AnesthesiaInterventiontramacet, naloxone; tramacet; AcetaminophenPhasePhase 3Registry statusCompletedThe Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache
NCT00574015 · start 2007-12
Registered record
- Registry ID
- NCT00574015
- Conditions
- Toothache
- Interventions
- hydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2013-01
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionToothacheInterventionhydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)PhasePhase 4Registry statusCompletedSafety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
NCT00654069 · start 2007-09
Registered record
- Registry ID
- NCT00654069
- Conditions
- Pain
- Interventions
- Placebo; Acurox 5/30 mg; Acurox 7.5/30
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2008-03
- Enrolment
- 405
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionPlacebo; Acurox 5/30 mg; Acurox 7.5/30PhasePhase 3Registry statusCompletedA Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100086 · start 2007-01
Registered record
- Registry ID
- NCT01100086
- Conditions
- Healthy Volunteers
- Interventions
- Reformulated OXY (oxycodone HCl); Original OxyContin® (OXY) (oxycodone HCl)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2007-06
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionReformulated OXY (oxycodone HCl); Original OxyContin® (OXY) (oxycodone HCl)PhasePhase 1Registry statusCompletedOpioid and Cannabinoid Pharmacokinetic Interactions
NCT00308555 · start 2006-05
Registered record
- Registry ID
- NCT00308555
- Conditions
- Pain
- Interventions
- Cannabis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2009-03
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionCannabisPhasePhase 1Registry statusCompleted